Unleashing nature’s manufacturing powerhouse.
B cells are nature’s exquisitely tuned medicine factories, manufacturing proteins to fight disease and maintain health. What if… we could engineer these cells to produce any therapeutic protein needed … allogeneically, without preconditioning, and redosably? The resulting new class of medicines – Engineered B Cell Medicines (BeCMs) – could be transformative.
Powerful & Durable
In nature, a single B cell can produce thousands of proteins per second at constant levels over decades. Leveraging this inherent power, our BeCMs could create previously impossible options for patients.
B Cells resist interference by outside agents, and have been notoriously intractable to therapeutically relevant engineering. Until now. Our tunable, site-specific, precision genome engineering results in BeCMs that produce proteins efficiently, with controlled, constant & consistent dosing (and redosing).
Plasma cells, terminally differentiated B cells, have evolved to be able to more easily evade immune detection, and they intrinsically traffic to and engraft in the bone marrow. These properties drive the potential for powerful off-the-shelf medicines without the need for the toxic preconditioning required in other classes of cellular medicine.
BeCMs can be engineered to produce a vast array of therapeutically important biologics without the burdens of other cellular medicines, driving exceptionally broad therapeutic application — across protein classes, patient populations, and therapeutic areas.
Our goal is to create a transformative new class of highly durable, off-the-shelf, re-dosable medicines that provide long-lasting production of therapeutic proteins: Engineered B Cell Medicines (BeCMs).
A Powerful Platform
We have built a powerful Engineered B cell medicines platform to deliver transformative therapies for patients, opening a new and paradigm-shifting class of cellular medicines.
Through precision engineering, we can create B cells designed to produce specific therapeutic proteins needed for a specific disease. The modularity of our platform allows us to develop medicines to treat a broad range of diseases.
Our therapies are based on a cell that naturally produces several thousand antibodies per second to prevent or reverse disease progression. BeCMs can also spare patients from potentially harmful side effects and invasive pre-treatment procedures that often accompany traditional cell and gene therapies.
We are building a broad portfolio initially across rare disease and oncology, and are currently moving these programs toward the clinic. As we advance, we will optimize multiple different prototypes, enabling expansion into new indications and therapeutic areas.
A Programmable Platform
PRECISE GENOME EDITING OF PERIPHERAL BLOOD B CELLS
This step is highly modular. Starting with circulating B cells, we use precision genome engineering to insert a gene into an exact chromosomal location. By swapping in different genes of interest, we can create new product candidates for multiple diseases.
ENGINEERED TO DIFFERENTIATE B CELLS INTO PROTEIN-SECRETING PLASMA CELLS
Engineered B cells are expanded and then, by changing culture conditions, they are differentiated into plasma cells that secrete the desired therapeutic protein. All of these steps have been optimized for scale-up and clinical manufacturing.
DESIGNED TO ACT AS MEDICINE FACTORIES
With the capacity to produce thousands of antibodies per cell every second, they are ready for patient treatment. When infused into patients, these plasma cells migrate to the bone marrow to produce the desired therapeutic protein at constant levels. Being terminally differentiated and more able to evade immune detection, these properties give our BeCMs a unique potential of both controlled and repeat dosing.